MeiraGTx Secures FDA RMAT Designation for Groundbreaking Parkinson’s Gene Therapy
MeiraGTx has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AAV-GAD, for Parkinson’s disease.
May 9, 2025

Written by Curation